Eisai Co., Ltd., commonly referred to as Eisai, is a prominent global pharmaceutical company headquartered in Japan. Established in 1941, Eisai has made significant strides in the healthcare industry, focusing on the discovery, development, and marketing of innovative medicines. With major operational regions across Asia, Europe, and North America, the company is dedicated to addressing unmet medical needs, particularly in neurology and oncology.
Eisai's core products include treatments for Alzheimer's disease and various cancers, distinguished by their commitment to patient-centric solutions. The company has achieved notable recognition for its research and development efforts, positioning itself as a leader in the pharmaceutical sector. With a strong emphasis on ethical practices and collaboration, Eisai continues to enhance its market presence while striving to improve the quality of life for patients worldwide.
+25 vs industry average
Eisai’s score of 63 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Eisai?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Eisai's reported carbon emissions
In 2024, Eisai Co., Ltd., headquartered in Japan, reported total greenhouse gas emissions of approximately 1.1 billion kg CO2e. This total comprises 45,666,000 kg CO2e from Scope 1 emissions, 3,921,000 kg CO2e from Scope 2 emissions, and 825,382,000 kg CO2e from Scope 3 emissions, specifically from purchased goods and services. Eisai has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 55% by fiscal 2030, using fiscal 2019 as the base year. Additionally, the company targets a 27.5% reduction in Scope 3 emissions (Category 1) within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and reflect Eisai's commitment to achieving net-zero emissions by 2050. The company has made significant strides in its emissions reduction strategy, with a clear focus on both near-term and long-term goals. Eisai's initiatives are crucial in the pharmaceutical sector, where sustainability practices are increasingly vital for corporate responsibility and environmental stewardship.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Eisai’s Climate Goals (2030 & 2050)
5 goals2030
55% reduction in Scope 2
Reduce Scope1 and Scope 2 GHG emissions by 55% by fiscal 2030 from base year fiscal 2019 Reduce Scope3 (Category 1) GHG emissions by 27.5% w…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 5 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsFrequently asked questions
Common questions about Eisai’s sustainability data and climate commitments
Data year: 2024
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project